Optos Plc
LONDON, UK, 29 June 2011 - Optos plc (LSE: OPTS), a leading medical retinal imaging company, announced that it reached an important milestone for its ultra-widefield retinal imaging product line – capturing images for 30 million optomap patients. For more than 10 years, Optos has helped eye care professionals diagnose, analyze and monitor ocular pathology in 82% of the retina, something no other device is capable of doing in any one image. More than 4,000 practices in 17 countries have helped Optos accomplish this milestone.
On May 17th, Albright & Schnulo Family Eye Care in Worthington, Ohio and an Optos customer since 2004 captured the image of the 30 millionth optomap® patient. Drs. Albright and Schnulo remarked, “Our office performs an optomap for every patient. We feel an ultra-widefield retinal image provides important information about the health of the central and peripheral areas of the retina. With optomap you can also see other potential health issues, such as diabetes and hypertension. We feel very good about providing the best care not only for our patients’ eyes but also for their overall health. It is an important part of a routine comprehensive eye exam.”
A simple optomap image is an important tool for the screening, early detection and diagnosis of eye problems such as retinal detachment, glaucoma, cataracts, retinal holes/retinal tears and age-related macular degeneration. It can also indicate evidence of non-eye diseases such as diabetes, hypertension and certain cancers. Many of these conditions can be seen in the periphery of the retina as well as in the central pole further supporting the value of widefield imaging. Recognizing its customers’ contributions to this achievement, Optos declared May 17th optomap day. As the specific office that took the 30 millionth optomap, Albright and Schnulo Family Eye Care will have a visit and lunch meeting with Roy Davis, CEO of Optos in their Ohio office. Mr. Davis commented, “Optos is dedicated to providing eye care professionals and their patients with the most advanced retinal imaging technologies to aid in the accurate diagnoses of diseases and help guide treatment plans. We are excited to reach this milestone as it demonstrates our customers’ beliefs that optomap benefits their patients and practices.”
Inquiries:
Optos Inc.
Leslie Amodei, Director Global Marketing
Tel: 508-787-1414
About Optos Plc
Optos plc is a leading retinal imaging company. Our vision is to be recognized as a leading provider of devices and solutions to ophthalmic professionals for improved patient care. Optos' core devices produce ultra wide-field, high resolution digital images of approximately 82% of the retina, something no other device is capable of doing in any one
image. The images provide optometrists and ophthalmologists with enhanced clinical information which facilitates the early detection, management and treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers.
Optos has a range of medical devices that support different customer segments and patient levels: the P200 and 200Dx devices are concentrated on wellness screening carried out by optometrists and ophthalmologists in primary care; the P200C device is designed to meet the need for more exacting clinical imaging capabilities and standards in secondary care within the ophthalmology market and at optometric practices that are clinically managing a patient base with advanced ocular disease; and the P200MA and 200Tx devices supports ophthalmologists and retinal specialists in the medical care market. Optos’ product range has recently been expanded to include the AccuPen, PachPen and B-Scan handheld devices for glaucoma and tumor management. The acquisition of Opto Global, completed in December 2010, brings additional devices for both optometrist and ophthalmologist practices, and expand the geographic reach outside our core North American and European markets.
For more information please visit our website www.optos.com